Celldex Completes CSU Trials Early, Raises $345M to Fuel Pipeline
Event summary
- Celldex completed enrollment in Phase 3 CSU studies six months ahead of schedule, enrolling 1,939 patients across 43 countries.
- The company raised $345 million in a follow-on public offering in April 2026, boosting its cash position to $451.5 million.
- Topline data from Phase 3 barzolvolimab CSU studies expected in Q4 2026, with BLA submission planned for 2027.
- Phase 2 studies in prurigo nodularis and atopic dermatitis completed enrollment, with topline data expected in summer and late 2026, respectively.
- Phase 1 proof of mechanism study for CDX-622 in asthma ongoing, with data anticipated in Q3 2026.
The big picture
Celldex's accelerated enrollment in its Phase 3 CSU studies and successful fundraising reflect strong investor confidence in its lead candidate, barzolvolimab. The company is positioning itself as a key player in the mast cell-targeting space, with a pipeline that addresses multiple inflammatory and autoimmune disorders. The strategic focus on data readouts and regulatory milestones underscores Celldex's shift from development-stage to potential commercialization phase.
What we're watching
- Regulatory Pathway
- Whether the topline data from Phase 3 CSU studies in Q4 2026 will support a successful BLA submission in 2027.
- Pipeline Momentum
- The pace at which Celldex can deliver multiple key data readouts across its pipeline in 2026.
- Financial Runway
- How the $345 million raised will be allocated to support commercialization preparations and growing pipeline.
Related topics